NewsRoom

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014

201320122011201020092008

Nov 10, 2020
--Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
Sep 9, 2020
- Strong cash position of ~$183 million at start of fiscal year 2021 -
Jul 2, 2020
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
May 26, 2020
- Event scheduled for June 2, 2020 at 8am ET; featuring leading KOL Matthew Matasar, M.D. -
May 13, 2020
- Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT -
May 7, 2020
-- ME-401 global alliance with Kyowa Kirin executed, $100M in upfront payment and MEI eligible to receive up to an additional $582.5M in milestones --